Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Interleukin-1 Inhibition to Improve the Response of Myeloproliferative Neoplasms Resistant to Cytoreductive Treatment (INTEREST)

12 de novembro de 2026 atualizado por: University Hospital, Brest

Myeloproliferative neoplasms (MPNs) - polycythemia vera, essential thrombocythemia, and primary myelofibrosis - are characterized by excessive myeloid proliferation driven by mutations affecting the JAK2, CALR, and MPL genes, resulting in constitutive activation of hematopoietic cytokine signaling pathways. These hematological malignancies carry an increased risk of thrombosis and may evolve toward secondary myelofibrosis or acute leukemia. Bone marrow inflammation, particularly through interleukin-1 (IL-1), plays a major role in clonal expansion and the clinical expression of these diseases, as demonstrated by preclinical models showing the beneficial effect of its inhibition.

Anakinra, an IL-1 receptor antagonist widely used in rheumatology but never evaluated in MPNs, represents a promising therapeutic option. This proof-of-concept study will randomize 50 patients with a suboptimal response to cytoreductive therapy into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or cytoreductive therapy alone (n=25). The primary endpoint will be the reduction in serum calprotectin levels, a key inflammatory marker of the IL-1 loop that has recently demonstrated prognostic relevance in MPNs. Secondary endpoints will include improvements in hematological parameters, driver mutation allelic burden, pro-inflammatory cytokines, and quality of life.

This study represents an essential step toward larger trials aimed at demonstrating a durable reduction in thrombotic risk and disease progression.

Visão geral do estudo

Status

Ainda não está recrutando

Intervenção / Tratamento

Descrição detalhada

Eligible patients will be identified during routine follow-up visits. After signature of informed consent and confirmation of all eligibility criteria - including a negative urine pregnancy test for women of childbearing potential - patients will be randomized into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or ongoing cytoreductive therapy alone (n=25), for a duration of 3 months.

Clinical and laboratory assessments (CBC, CRP, circulating CD34+ cells, allelic burden, calprotectin, cytokines, quality of life) will be performed at baseline, at 3 months, and at 6 months. An additional visit at 1 month is planned in the anakinra arm to assess tolerability. Patients may withdraw at any time, with reasons documented in the eCRF.

The addition of an anti-IL-1 treatment to cytoreductive therapy could improve its efficacy by promoting control of the mutated clone, which is poorly targeted by current cytoreductive agents other than interferon-α, often poorly tolerated. Better clonal control could limit phenotypic progression, reduce thrombotic risk, and improve hematological response, particularly in the megakaryocytic lineage.

The impact on myelofibrosis, observed in mice, and the improvement in quality of life through reduction of systemic inflammation remain to be confirmed in humans. Not all patients will necessarily benefit from this approach, justifying this exploratory study to evaluate its potential and feasibility.

The risks associated with anakinra are predictable and well documented (local reactions, minor systemic effects, infectious risk), mitigated by the short treatment duration and close monitoring. The benefit-risk ratio is considered favorable.

Tipo de estudo

Intervencional

Inscrição (Estimado)

50

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Diagnosis of MPN: PV, ET, or PMF according to WHO criteria
  • Stable cytoreductive therapy for at least 6 months
  • Incomplete hematologic response according to ELN criteria, excluding bone marrow, OR complete hematologic response with anemia in ET, OR persistence of general clinical symptoms (fever, night sweats, pruritus, fatigue > 5/10 on VAS)
  • Adult patient capable of providing informed consent

Exclusion Criteria:

  • Recurrent or poorly controlled infections
  • Thrombocytopenia < 100 G/L
  • Neutropenia < 1 G/L
  • Hypersensitivity to the active substance, any excipients, or proteins derived from Escherichia coli
  • Concomitant immunosuppressive therapy
  • Refusal to participate
  • Patient under legal protection (guardianship, curatorship, etc.)
  • Patients unable to consent.
  • Positive urine pregnancy test at screening / pregnant or breastfeeding women.
  • Lack of understanding of questionnaires or inability to follow up.
  • Women of childbearing potential unwilling to use a highly effective contraceptive methods

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Anakinra + cytoreductive therapy

Anakinra 100 mg/day subcutaneously for 3 months, added to ongoing standard cytoreductive therapy (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. Additional Month 1 safety/tolerability visit (clinical exam, routine biology, AE/SAE and injection-site reaction review, compliance check) and an injection diary for adherence.

Recombinant human interleukin-1 receptor antagonist (Kineret 100 mg/0.67 mL prefilled syringe). Administered at 100 mg once daily by subcutaneous injection for 3 months, in addition to ongoing standard cytoreductive therapy. Self-injection or home-nurse administration; adherence tracked via injection diary.

Sem intervenção: Cytoreductive therapy alone

Standard cytoreductive therapy continued alone, with no additional study treatment (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. No Month 1 visit.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in serum calprotectin levels
Prazo: Baseline and Month 3

Calprotectin levels are measured on serum samples by centralized analysis (µg/mL)

Baseline and Month 3

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Improvement (yes/no) of the response status between baseline and month 3.
Prazo: Month 3

Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

Month 3
Improvement (yes/no) of the response status between baseline and month 6.
Prazo: Month 6

Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

Month 6
Improvement (yes/no) of the response status between month 3 and month 6.
Prazo: Month 6

Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

Month 6
Hemoglobin count
Prazo: Baseline

Measurement of Hemoglobin in g/dL

Baseline
Hematocrit count
Prazo: Baseline

Measurement of Hematocrit in %

Baseline
White blood cell count
Prazo: Baseline

Measurement of WBC in G/L

Baseline
Platelet cell count
Prazo: Baseline

Measurement of Platelets in G/L

Baseline
Hemoglobin count
Prazo: Month 3

Measurement of Hemoglobin in g/dL

Month 3
Hematocrit count
Prazo: Month 3

Measurement of Hematocrit in %

Month 3
White blood cell count
Prazo: Month 3

Measurement of WBC in G/L

Month 3
Platelet cell count
Prazo: Month 3

Measurement of Platelets in G/L

Month 3
Hemoglobin count
Prazo: Month 6

Measurement of Hemoglobin in g/dL

Month 6
Hematocrit count
Prazo: Month 6

Measurement of Hematocrit in %

Month 6
White blood cell count
Prazo: Month 6

Measurement of WBC in G/L

Month 6
Platelet cell count
Prazo: Month 6

Measurement of Platelets in G/L

Month 6
Treatment-related adverse event for experimental group
Prazo: Month 1

A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

Month 1
Treatment-related adverse event for experimental group
Prazo: Month 3

A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

Month 3
Treatment-related adverse event for experimental group
Prazo: Month 6

A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

Month 6
Adherence to treatment regimen for experimental group
Prazo: Month 1

Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between baseline and month 1. Days with missing diary entries will be excluded from the calculation.

Month 1
Adherence to treatment regimen for experimental group
Prazo: Month 2

Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 1 and month 2. Days with missing diary entries will be excluded from the calculation

Month 2
Adherence to treatment regimen for experimental group
Prazo: Month 3

Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 2 and month 3. Days with missing diary entries will be excluded from the calculation.

Month 3
QLQ-C30 Summary Score
Prazo: Baseline

The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

Baseline
QLQ-C30 Summary Score
Prazo: Month 3

The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

Month 3
QLQ-C30 Summary Score
Prazo: Month 6

The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

Month 6
Global health status / QoL score
Prazo: Baseline

Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

Baseline
Global health status / QoL score
Prazo: Month 3

Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

Month 3
Global health status / QoL score
Prazo: Month 6

Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

Month 6
Patient-reported symptom severity over the previous 4 weeks for pruritus
Prazo: Baseline

Defined as the score on a 10-point Visual Analog Scale

Baseline
Patient-reported symptom severity over the previous 4 weeks for fever
Prazo: Baseline

Defined as the score on a 10-point Visual Analog Scale

Baseline
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Prazo: Baseline

Defined as the score on a 10-point Visual Analog Scale

Baseline
Patient-reported symptom severity over the previous 4 weeks for pruritus
Prazo: Month 3

Defined as the score on a 10-point Visual Analog Scale

Month 3
Patient-reported symptom severity over the previous 4 weeks for fever
Prazo: Month 3

Defined as the score on a 10-point Visual Analog Scale

Month 3
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Prazo: Month 3

Defined as the score on a 10-point Visual Analog Scale

Month 3
Patient-reported symptom severity over the previous 4 weeks for pruritus
Prazo: Month 6

Defined as the score on a 10-point Visual Analog Scale

Month 6
Patient-reported symptom severity over the previous 4 weeks for fever
Prazo: Month 6

Defined as the score on a 10-point Visual Analog Scale

Month 6
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Prazo: Month 6

Defined as the score on a 10-point Visual Analog Scale

Month 6
Inflammatory biological profile
Prazo: Baseline

Measurement of IL-1β cytokines in pg/mL.

Baseline
Inflammatory biological profile
Prazo: Month 3

Measurement of IL-1β cytokines in pg/mL.

Month 3
Inflammatory biological profile
Prazo: Month 6

Measurement of IL-1β cytokines in pg/mL.

Month 6
Inflammatory biological profile
Prazo: Baseline

Measurement of IL-6 cytokines in pg/mL.

Baseline
Inflammatory biological profile
Prazo: Month 3

Measurement of IL-6 cytokines in pg/mL.

Month 3
Inflammatory biological profile
Prazo: Month 6

Measurement of IL-6 cytokines in pg/mL.

Month 6
Inflammatory biological profile
Prazo: Baseline

Measurement of IL-8 cytokines in pg/mL.

Baseline
Inflammatory biological profile
Prazo: Month 3

Measurement of IL-8 cytokines in pg/mL.

Month 3
Inflammatory biological profile
Prazo: Month 6

Measurement of IL-8 cytokines in pg/mL.

Month 6
Inflammatory biological profile
Prazo: Baseline

Measurement of MIP-1β cytokines in pg/mL.

Baseline
Inflammatory biological profile
Prazo: Month 3

Measurement of MIP-1β cytokines in pg/mL.

Month 3
Inflammatory biological profile
Prazo: Month 6

Measurement of MIP-1β cytokines in pg/mL.

Month 6
Inflammatory biological profile
Prazo: Baseline

Measurement of TNF-α cytokines in pg/mL.

Baseline
Inflammatory biological profile
Prazo: Month 3

Measurement of TNF-α cytokines in pg/mL.

Month 3
Inflammatory biological profile
Prazo: Month 6

Measurement of TNF-α cytokines in pg/mL.

Month 6
Allele burden of the driver mutation
Prazo: Baseline

Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

Baseline
Allele burden of the driver mutation
Prazo: Month 3

Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

Month 3
Allele burden of the driver mutation
Prazo: Month 6

Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

Month 6
Allele burden of the driver mutation
Prazo: Baseline

Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

Baseline
Allele burden of the driver mutation
Prazo: Month 3

Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

Month 3
Allele burden of the driver mutation
Prazo: Month 6

Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

Month 6
Allele burden of the driver mutation
Prazo: Baseline

Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

Baseline
Allele burden of the driver mutation
Prazo: Month 3

Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

Month 3
Allele burden of the driver mutation
Prazo: Month 6

Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

Month 6
Fibrosis markers
Prazo: Baseline

Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

Baseline
Fibrosis markers
Prazo: Month 3

Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

Month 3
Fibrosis markers
Prazo: Month 6

Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

Month 6

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de fevereiro de 2027

Conclusão Primária (Estimado)

1 de agosto de 2028

Conclusão do estudo (Estimado)

1 de agosto de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

3 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever